Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With TACE in Intermediate-stage Unresectable Hepatocellular Carcinoma
NCT05925413Phase 2Unknown
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Eastern Hepatobiliary Surgery Hospital. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05925413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925413.